Cutaneous lupus erythematosus (CLE) is an autoimmune skin disease occurring in association with or without systemic lupus erythematosus (SLE). Although antimalarials are widely used as the first-line systemic agent, refractory cases may benefit from additional immunomodulators, immunosuppressives, and biologics. An interest in biological therapies for CLE has emerged in recent years due to novel insight into the pathogenesis of CLE. These targets include B cells, T cells, and cytokines that are involved in immune system pathways. Currently belimumab is the only biological therapy approved for SLE and no biologic has been approved for CLE. While there is a paucity of high quality evidence with regard to biologics in CLE management, trials are currently being performed to determine their role.
HejaziEZWerthVP. Cutaneous lupus erythematosus: an update on pathogenesis, diagnosis and treatment. Am J Clin Dermatol2016; 17: 135–146.
2.
AlbrechtJTaylorLBerlinJA. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol2005; 125: 889–894.
3.
KleinRMoghadam-KiaSLoMonicoJ. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol2011; 147: 203–208.
4.
KasperkiewiczMEmingRBehzadM. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges2012; 10: 727–732.
5.
VitalEMWittmannMEdwardS. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol2015; 67: 1586–1591.
6.
AlsanafiSKovarikCMermelsteinALWerthVP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol2011; 17: 142–144.
ManziSSanchez-GuerreroJMerrillJT. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis2012; 71: 1833–1888.
9.
Hui-YuenJSReddyATaylorJ. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol2015; 42: 2288–2295.
KhamashtaMMerrillJTWerthVP. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. Epub ahead of print 2016.
12.
Furie R, Merrill JT, Werth VP, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum 2015; 67: #3223 (abstract).
13.
JabbariASuarez-FarinasMFuentes-DuculanJ. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. J Invest Dermatol2014; 134: 87–95.
14.
Werth VP, Fiorentino D, Cohen SG, et al. A phase I single-dose crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus. Arthritis Rheum 2013; 65: #1608 (abstract).
15.
Sullivan BA, Guzman R, Russel CB, et al. Molecular, cellular and histopathologic assessment of baseline characteristics of sixteen subjects with discoid lupus erythematosus prior to treatment with AMG 811 (anti-IFNg). Arthritis Rheum 2014; 66: S725: #1646 (abstract).
16.
Linker-IsraeliMDeansRJWallaceDJ. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol1991; 147: 117–123.
17.
SzepietowskiJCNilganuwongSWozniackaA. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum2013; 65: 2661–2671.
18.
De SouzaAAli-ShawTStroberBEFranksAGJr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol2011; 147: 896–898.
19.
WinchesterDDuffinKCHansenC. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus2012; 21: 1007–1010.
20.
DahlCJohansenCKragballeKOlesenAB. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol2013; 93: 368–369.
De PitaOBellucciAMRuffelliM. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus1997; 6: 415–417.
23.
LampropoulosCEHughesGRDPDC. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol2007; 26: 981–983.
24.
KyCSwasdibutraBKhademiS. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatol Reports2015; 7: 5804–5804.
25.
Mellor-PitaSCitoresMJCastejonR. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis2006; 65: 553–554.
26.
FranzBFritzschingBRiehlA. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum2007; 56: 1910–1920.
27.
BombardierCGladmanDDUrowitzMB. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum1992; 35: 630–640.
28.
JollyMKazmiNMikolaitisRA. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol2013; 68: 618–623.
